NON-CIRRHOTIC NON-ALCOHOLIC STEATOHEPATITIS WITH FIBROSIS

Clinical trials for NON-CIRRHOTIC NON-ALCOHOLIC STEATOHEPATITIS WITH FIBROSIS explained in plain language.

Never miss a new study

Get alerted when new NON-CIRRHOTIC NON-ALCOHOLIC STEATOHEPATITIS WITH FIBROSIS trials appear

Sign up with your email to follow new studies for NON-CIRRHOTIC NON-ALCOHOLIC STEATOHEPATITIS WITH FIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New drug tested to halt scarring in fatty liver disease

Disease control Completed

This study tested whether a drug called cotadutide is safe and can help people with a type of fatty liver disease called NASH, which causes liver scarring. Fifty-four adults with confirmed liver scarring received either the drug or a placebo for about six months. The main goals w…

Matched conditions: NON-CIRRHOTIC NON-ALCOHOLIC STEATOHEPATITIS WITH FIBROSIS

Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Mar 30, 2026 14:30 UTC

NON-CIRRHOTIC NON-ALCOHOLIC STEATOHEPATITIS WITH FIBROSIS

Get alerted when new NON-CIRRHOTIC NON-ALCOHOLIC STEATOHEPATITIS WITH FIBROSIS trials appear

New drug tested to halt scarring in fatty liver disease